| 产品名称 | Peptides EP11250_1 | HIV Gag 433-440 (HLA-A*02:01) |
|---|---|
| 目录号 | EP11250_1 |
| 别名 | HIV Gag 433-440 (HLA-A*02:01) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP11250_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP11250_1 | HIV Gag 433-440 (HLA-A*02:01)
品名:HIV Gag 433-440 (HLA-A*02:01)
货号:EP11250_1
规格:1 mg; 5 mg
品牌:Peptides.de
产品描述
Therapeutic vaccination of chronically infected HIV-1 subjects was evaluated as a means of halting disease progression. A subdominant peptide vaccine containing 15 CTL epitopes and 3 helper T-cell peptides along with an adjuvant was delivered to 18 infected subjects. Using IFN-? EliSpot, 9 new T-cell responses were detected in 6/14 subjects whose viral loads (VL) remained stable. 7/10 CTL and other pre-existing responses, however, were not significantly detected. Gag433, FLGKIWPS, is a CTL epitope sequence used as a vaccine component.
| Protein | Envelope glycoprotein gp160 |
| Species | HIV |
| Application | Flow Cytometry, Immunohistochemistry |
| Indication | Infectious disease |